Hepatology

CMR CureDiab GmbH

Heidi Rohwer, 17 March, 2026, 0

A first-in-class approach to treat fatty liver, fibrosis and obesity by using a small molecule.

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR

Aviso de cookies

Hepatology

CMR CureDiab GmbH

Capital Cell Barcelona

Links

About cookies

Hepatology

CMR CureDiab GmbH

Capital Cell Barcelona

Links

About cookies

Log in with your credentials

Forgot your details?

Create Account